XBiotech discontinues its phase III trial & more — 6 GI company key notes

Here are six updates on GI companies from the past week.

After early findings were "not sufficient to meet efficacy," XBiotech discontinued the phase III study of its novel candidate antibody therapy for colorectal cancer.

Takeda Pharmaceuticals is relocating approximately 100 researchers to Boston during fiscal year 2017.

Boston Scientific is investing $19 million in a new Galway, Ireland-based RoadRunner endoscopy design facility.

The FDA awarded Becton, Dickinson and Company's BD Max's extended enteric bacterial panel 510(k) clearance.

Level Ex CEO and Founder Sam Glassenberg is working to address how gastroenterologists can virtually practice their craft through the company's app, GastroEx.

Numerate entered into an agreement with Takeda to use its artificial intelligence engines to develop clinical candidates in multiple specialties.

More articles on gastroenterology:
5 stats on GI net revenue per case at multispecialty ASCs
GI leader to know: Dr. Namita Pareek of Gastroenterology Associates of Gainesville
5 thoughts from a first-year GI fellow

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months